# OnCo record leuprolide (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/leuprolide/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "leuprolide" ;
  schema:name "Leuprolide (leuprorelin) and GnRH agonists"@en ;
  schema:alternateName "Leuprorelin"@en, "Leuprolide acetate"@en, "GnRH agonist"@en, "Lupron / Eligard / Camcevi" ;
  schema:description "Leuprolide is the injectable that shuts off testosterone production, the foundation of hormone therapy for prostate cancer since the 1980s; it is also used for ovarian suppression in premenopausal breast cancer."@en ;
  schema:url <https://onco.cc/drugs/leuprolide/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Leuprorelin> ;
  owl:sameAs <http://www.wikidata.org/entity/Q907160> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=leuprolide> ;
  onco:status "approved" ;
  onco:tag "gap-fill", "generic" ;
  onco:modality "GnRH agonist depot" ;
  onco:approval "US 1985: Palliative treatment of advanced prostate cancer", "US 1989: Depot formulation (Lupron Depot)" ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/salivary-duct-carcinoma/> ;
  onco:technologies <https://onco.cc/technologies/androgen-deprivation/>, <https://onco.cc/technologies/endocrine-therapy/> ;
  onco:targets <https://onco.cc/targets/androgen-receptor/> ;
  onco:companies <https://onco.cc/companies/abbvie/>, <https://onco.cc/companies/takeda/>, <https://onco.cc/companies/foresee-pharmaceuticals/>, <https://onco.cc/companies/oakwood-laboratories/> ;
  onco:terms <https://onco.cc/terms/castration-resistance/>, <https://onco.cc/terms/ovarian-function-suppression/> .